Gates Foundation Strategic Investment Fund Logo
Share this page:

BioNTech Announces New Collaboration to Develop HIV and Tuberculosis Programs

MAINZ, Germany–(BUSINESS WIRE)–BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, announced today that it has signed an agreement with the Bill & Melinda Gates Foundation (the Gates Foundation) to develop HIV and tuberculosis programs, further expanding the Company’s infectious disease portfolio.

Read the full article here.